Historical First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

Amer Zeidan, MBBS, explains the treatment options for patients with lower-risk MDS prior to the approval of luspatercept.

EP: 1.Diagnosing Lower-Risk Myelodysplastic Syndromes (LR-MDS)

EP: 2.Risk Stratification in MDS

Now Viewing

EP: 3.Historical First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP: 4.Luspatercept for Patients With Lower-Risk MDS: Data from the COMMANDS Trial

EP: 5.Clinical Implications of the COMMANDS Trial in the Treatment of Lower-Risk MDS

Related Videos